The biomarkers associated with non-dipper pattern in patients with type 2 diabetes with hypertension.

Viorel Manea, Daniel-Corneliu Leucuţa, Călin Pop, Mircea-Ioachim Popescu
Author Information
  1. Viorel Manea: Department of Cardiology, "Constantin Opriş" Emergency County Clinical Hospital, Baia Mare, Romania.
  2. Daniel-Corneliu Leucuţa: Department of Medical Informatics and Biostatistics, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  3. Călin Pop: Department of Cardiology, "Constantin Opriş" Emergency County Clinical Hospital, Baia Mare, Romania.
  4. Mircea-Ioachim Popescu: Department of Cardiology, Emergency County Clinical Hospital, Oradea, Romania.

Abstract

Background and aims: The non-dipper pattern is present in about 50 percent of patients with type 2 diabetes (T2D) and hypertension, a status associated with more frequent cardiovascular complications and restrained prognosis. This study aimed to identify simple biomarkers that can be used for the classification of dipper and non-dipper individuals with type 2 diabetes and hypertension.
Method: 138 consecutive patients with type 2 diabetes mellitus (DM) and hypertension underwent 24-hour ambulatory blood pressure monitoring (ABPM), 54 (39.1%) dippers and 84 (60.9%) non-dippers; CBC and determinations of different biomarkers, as well as their ratio was also performed, for comparing the two dipper profiles. The different dipper profiles were established by ABPM, which highlights the mean arterial pressure (MAP), the mean heart rate (MHR), and the mean pulse pressure (MPP). The area under the receiver operating characteristic curve (AUC) was used to evaluate the ability of biomarkers to differentiate dippers from non-dippers.
Results: The study included 54 dipper and 84 non-dipper patients. The median age was 64 years (interquartile range 58-74), ranging from 24 to 85 years. The comparison between dipper and non-dipper in patients with type 2 diabetes and hypertension concerning different biomarkers found only two that were statistically significant: triglycerides to hemoglobin A1c (HbA1c) ratio and triglycerides to glucose ratio. For both biomarkers, the dippers had higher values than non-dippers. The best AUCs were found for triglycerides (Trig) to glucose ratio of 0.774 (95% confidence interval 0.601 - 0.92), statistically significant, followed at a distance by lymphocytes, platelets-lymphocytes ratio (PLR), platelet distribution width (PDW-SD), mean platelet volume (MPV) /Lymphocytes, and others, none of them being statistically significant.
Conclusions: This study offers valuable insights into the classification of dipper and non-dipper individuals with type 2 diabetes and hypertension using several biomarkers. Notably, the triglyceride-to-glucose ratio appeared as a significant marker with considerable discriminative capacity, indicating its potential therapeutic value in risk stratification and personalized treatment strategies.

Keywords

References

  1. Circ J. 2023 Feb 24;87(3):456-462 [PMID: 36261331]
  2. Cureus. 2022 Aug 19;14(8):e28176 [PMID: 36148183]
  3. Front Cardiovasc Med. 2023 Sep 25;10:1172178 [PMID: 37817864]
  4. Medicine (Baltimore). 2016 Oct;95(43):e4821 [PMID: 27787357]
  5. Diabetes Metab Syndr Obes. 2022 Nov 22;15:3617-3626 [PMID: 36444389]
  6. BMJ Open. 2016 Feb 23;6(2):e010456 [PMID: 26908530]
  7. J Hum Hypertens. 2014 Oct;28(10):567-74 [PMID: 24500721]
  8. J Clin Med. 2022 Mar 31;11(7): [PMID: 35407558]
  9. Rev Cardiovasc Med. 2024 Aug 20;25(8):294 [PMID: 39228482]
  10. Eur J Clin Invest. 2020 May;50(5):e13230 [PMID: 32291748]
  11. J Clin Hypertens (Greenwich). 2011 Apr;13(4):244-51 [PMID: 21466619]
  12. Medicine (Baltimore). 2020 May;99(19):e20190 [PMID: 32384513]
  13. J Clin Hypertens (Greenwich). 2023 Aug;25(8):700-707 [PMID: 37464585]
  14. Cureus. 2023 Aug 31;15(8):e44496 [PMID: 37791223]
  15. Eur J Intern Med. 2024 Aug;126:1-15 [PMID: 38914505]
  16. Clin Hypertens. 2021 Nov 15;27(1):22 [PMID: 34776006]
  17. Biomark Med. 2019 Apr;13(5):371-378 [PMID: 30919653]
  18. Diabetes Res Clin Pract. 2019 Nov;157:107843 [PMID: 31518657]
  19. J Am Med Inform Assoc. 2022 Oct 7;29(11):1829-1837 [PMID: 35927964]
  20. Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33 [PMID: 33298413]
  21. Life (Basel). 2023 Feb 25;13(3): [PMID: 36983796]
  22. Cardiovasc Diabetol. 2022 Aug 13;21(1):156 [PMID: 35964050]
  23. Front Endocrinol (Lausanne). 2022 Dec 15;13:1012383 [PMID: 36589799]
  24. BMC Cardiovasc Disord. 2021 Mar 16;21(1):139 [PMID: 33726683]
  25. Cardiovasc Diabetol. 2022 May 6;21(1):68 [PMID: 35524263]
  26. Iran J Kidney Dis. 2019 Mar;13(2):105-112 [PMID: 30988247]
  27. J Diabetes Res. 2024 Jan 11;2024:5287580 [PMID: 38239233]
  28. Platelets. 2015;26(7):680-1 [PMID: 25549287]
  29. N Engl J Med. 2006 Jun 1;354(22):2368-74 [PMID: 16738273]
  30. J Assoc Physicians India. 2022 Apr;70(4):11-12 [PMID: 35443358]
  31. Clin Exp Hypertens. 2013;35(8):570-3 [PMID: 23387864]
  32. Cardiovasc Diabetol. 2022 Aug 23;21(1):161 [PMID: 35999546]
  33. Eur Heart J. 2018 Sep 1;39(33):3021-3104 [PMID: 30165516]
  34. Clin Exp Hypertens. 2014;36(4):217-21 [PMID: 23786430]
  35. Curr Opin HIV AIDS. 2010 Nov;5(6):463-6 [PMID: 20978388]
  36. BMC Cardiovasc Disord. 2024 Apr 01;24(1):189 [PMID: 38561664]

Word Cloud

Created with Highcharts 10.0.0biomarkersrationon-dippertype2diabeteshypertensiondipperpatientsmeanstudypressuredippersnon-dippersdifferentstatisticallytriglycerides0significantpatternassociatedusedclassificationindividualsABPM5484twoprofilesyearsfoundglucoseplateletBackgroundaims:present50percentT2DstatusfrequentcardiovascularcomplicationsrestrainedprognosisaimedidentifysimplecanMethod:138consecutivemellitusDMunderwent24-hourambulatorybloodmonitoring391%609%CBCdeterminationswellalsoperformedcomparingestablishedhighlightsarterialMAPheartrateMHRpulseMPPareareceiveroperatingcharacteristiccurveAUCevaluateabilitydifferentiateResults:includedmedianage64interquartilerange58-74ranging2485comparisonconcerningsignificant:hemoglobinA1cHbA1chighervaluesbestAUCsTrig77495%confidenceinterval601-92followeddistancelymphocytesplatelets-lymphocytesPLRdistributionwidthPDW-SDvolumeMPV/LymphocytesothersnoneConclusions:offersvaluableinsightsusingseveralNotablytriglyceride-to-glucoseappearedmarkerconsiderablediscriminativecapacityindicatingpotentialtherapeuticvalueriskstratificationpersonalizedtreatmentstrategiesplatelet-lymphocytestriglycerides-glucose

Similar Articles

Cited By

No available data.